enGene Announces Preliminary Data Update from Pivotal LEGEND Trial in Bladder Cancer
I'm PortAI, I can summarize articles.
enGene Holdings Inc. will host a conference call and webcast on November 11, 2025, at 8:00 a.m. ET to discuss preliminary data from the pivotal LEGEND trial, which evaluates its gene therapy candidate, detalimogene voraplasmid, in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. A slide deck will be available before the call, and a replay will be accessible on the company's website for one year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments